Silverback Therapeutics, Inc. (SBTX) Financial Analysis & Valuation | Quarter Chart
Silverback Therapeutics, Inc. (SBTX)
SBTXPrice: $5.87
Fair Value: 🔒
🔒score
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by t... more
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics fo... more
Description
Shares
| Market Cap | $550.43M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Peter A. Thompson |
| IPO Date | 2020-12-03 | CAGR | — |
| Employees | 90 | Website | www.silverbacktx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SBTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $527.50M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 7.13 | P/B Ratio | 4.19 |
| P/CF Ratio | -15.27 | P/FCF Ratio | -15 |
| EPS | — | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 22367.8% | Gross Margin | 0.94% |
| Operating Margin | -0.53% | Profit Margin | -0.43% |
| ROE | -0.22% | ROA | -0.15% |
| ROCE | -0.22% | Current Ratio | 6.17 |
| Quick Ratio | 5.98 | Cash Ratio | 1.13 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 2.48 | Piotroski Score | 1 |